Learn peptides step by step

September 2026 Peptide Research Signals: Access, Pipelines, and Quality

The loudest peptide stories are moving at different speeds. PCAC recommendations await FDA action, oral GLP-1 access is real, and the next obesity programs still have filing or review milestones ahead.

GLP-1 Adherence Starts With Perceived Competence: Why the Best Plans Feel Simple

People do not stay on GLP-1 plans because they are disciplined forever. They stay on them when the plan feels manageable, repeatable, and clear enough to trust on a busy week.

10m

Retatrutide Compounding Quality Control: Why the Debate Matters More Than Hype

Retatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.

10m

Retatrutide Early Access: What It Signals for Obesity Treatment, Timing, and Body Composition

Retatrutide is moving from conference noise into real-world access. That shift changes the conversation from headline weight loss to who gets treated, what gets monitored, and how body composition holds up.

Retatrutide in 2026: Why the Strongest Weight-Loss Signal Still Needs Body-Composition Tracking

Retatrutide is still the loudest metabolic signal in the room. The people who get the best result are the ones who track body composition, not just pounds lost.

Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist

Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.

Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols

Amycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.

Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack

Same company family of ideas — GLP-1 + amylin — two product architectures. Here's how amycretin compares to CagriSema without fake head-to-head rankings.

Cagrilintide Dosing Guide: Solo vs CagriSema 2.4 mg Weekly

Cagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.

CT-388 Dosing Guide: Weekly Dual GLP-1/GIP Up to 24 mg

CT-388 is Roche's weekly tirzepatide-class dual agonist with Phase 2 doses up to 24 mg. Here's the dosing vocabulary and the weight-loss signal searchers want.

Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters

Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.

Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol

Searching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.

Eloralintide + GLP-1 / Tirzepatide: The Amylin Add-On Stack Explained

Amylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.

SafetyIntermediate

Eloralintide Side Effects: What Phase 2 Tolerability Data Suggests

Amylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.

Eloralintide vs Cagrilintide: Amylin Agonists Compared

Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.

Eloralintide vs Petrelintide: Lilly vs Roche Amylin Agonists

Two weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.

Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3

Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.

ResearchBeginner

Macupatide Beginner's Guide: Lilly's LY3532226 Pipeline Peptide

Macupatide is the Lilly code name beside eloralintide that most people skip. This beginner guide explains what it is — and what not to invent about dosing yet.

Macupatide and Eloralintide: Lilly's Next Amylin Combination Angle

Eloralintide is only half the Lilly amylin headline. Macupatide shows up in the same ClinicalTrials.gov cluster. Here's the combo literacy guide.

SafetyIntermediate

MariTide Beginner's Guide: What Maridebart Cafraglutide Is

MariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.

MariTide Dosing Guide: Once-Monthly 140–420 mg Phase 2 Map

MariTide is the once-monthly obesity candidate people keep comparing to weekly GLP-1s. Here's the Phase 2 dosing map — 140 / 280 / 420 mg and the escalation arms that mattered for tolerability.

SafetyIntermediate

MariTide Side Effects: GI Tolerability and Monthly Titration

Monthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.

MariTide vs Weekly GLP-1s: Monthly Conjugate vs Weekly Agonists

Weekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.

Mazdutide Dosing Guide: 4 mg and 6 mg Weekly Protocols Explained

Mazdutide is a once-weekly glucagon/GLP-1 dual agonist with clear Phase 3 dose anchors at 4 mg and 6 mg. Here's the dosing and results map searchers want.

Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg

Orforglipron is Lilly's once-daily oral small-molecule GLP-1. Here's the titration ladder searchers want — 1 mg start, step-ups every four weeks, and Phase 3 maintenance doses.

Petrelintide Beginner's Guide: Roche/Zealand's Weekly Amylin Analog

Petrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.

Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration

Petrelintide is the Roche/Zealand once-weekly amylin analog drawing GLP-1-level attention for tolerability. Here's the Phase 2 dosing pattern, results, and what to track.

Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity

Survodutide is Boehringer's glucagon/GLP-1 dual agonist. Here's the dosing map from dose-finding through Phase 3 — weekly mg ranges, escalation logic, and what the weight-loss data showed.

MOTS-c and the Repair Paradox: Why a Metabolic Signal Is Not the Same as Healing

MOTS-c looks interesting because it can push metabolism in the right direction and still pull repair in the wrong one. The new data are a reminder that pathway activation and tissue healing are not the same thing.

Retatrutide, Protein, and Training: The Real-World Checklist for Better Body Composition

Retatrutide changes the appetite game fast. The people who get the best result are the ones who keep protein, training, and waist measurements in view at the same time.

Retatrutide Weight-Loss Data: What the New Numbers Mean for Body Composition

Retatrutide is forcing a better conversation about fat loss. The scale matters, but body composition, protein, and strength tell you whether the result will hold.

Retatrutide's FDA Watch Tightens After the Latest Obesity Trial Results

Retatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.

Retatrutide and Waist Circumference: Why the Scale Misses the Real Signal

Retatrutide can change weight fast enough to dominate the headline, but the better question is whether the loss is moving the right tissues, the right labs, and the right habits. That is where waist circumference becomes more useful than the scale.

10m

Retatrutide's July 23 Phase 3 Readout Keeps Raising the Ceiling

Retatrutide just posted two more strong phase 3 wins. The new numbers matter, but the bigger story is how phase 1, phase 2, and phase 3 now line up into one very clear dose-response story.

GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition

GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.

Retatrutide and Visceral Fat: Why the Scale Misses the Real Signal

Scale weight is noisy. If you are using retatrutide, waist trend, body composition, protein intake, and strength matter more than a single weigh-in.

What Real-World GLP-1 Data Actually Tells Us About Safety and Results

Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.

Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means

Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.

Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds

Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?

GLP-1s and Breast Cancer Risk: What the New Signal Means

GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.

Amylin and GLP-1: The Next Wave of Metabolic Peptides

The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.

GLP-1s and Macular Degeneration: What the Eye Studies Say

GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.

Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means

Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.

Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide

The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.

Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means

31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.

Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard

New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.

GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found

You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.

Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss

Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.